NasdaqCM - Delayed Quote USD

Orgenesis Inc. (ORGS)

0.5071 -0.0058 (-1.13%)
At close: April 26 at 4:00 PM EDT
0.5120 +0.00 (+0.97%)
After hours: April 26 at 6:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
530.0000
530.0000
36,025.0000
35,502.0000
7,652.0000
Cost of Revenue
6,255.0000
6,255.0000
5,133.0000
28,889.0000
31,099.0000
Gross Profit
-5,725.0000
-5,725.0000
30,892.0000
6,613.0000
-23,447.0000
Operating Expense
49,166.0000
49,166.0000
38,433.0000
21,135.0000
72,334.0000
Operating Income
-54,891.0000
-54,891.0000
-7,541.0000
-14,522.0000
-95,781.0000
Net Non Operating Interest Income Expense
-2,174.0000
-2,174.0000
-1,826.0000
-718.0000
-901.0000
Other Income Expense
-7,380.0000
-7,380.0000
-2,593.0000
-2,711.0000
-54.0000
Pretax Income
-64,445.0000
-64,445.0000
-11,960.0000
-17,951.0000
-96,736.0000
Tax Provision
473.0000
473.0000
209.0000
108.0000
-1,609.0000
Net Income Common Stockholders
-55,361.0000
-55,361.0000
-14,889.0000
-18,053.0000
6,270.0000
Diluted NI Available to Com Stockholders
-55,361.0000
-55,361.0000
-14,889.0000
-18,053.0000
6,270.0000
Basic EPS
-1.91
-1.91
-0.59
-0.74
0.29
Diluted EPS
-1.91
-1.91
-0.59
-0.74
0.29
Basic Average Shares
29,007.8690
29,007.8690
25,096.2840
24,273.6580
21,320.3140
Diluted Average Shares
29,007.8690
29,007.8690
25,096.2840
24,273.6580
21,320.3140
Total Operating Income as Reported
-53,636.0000
-53,636.0000
-10,110.0000
-16,800.0000
-95,785.0000
Rent Expense Supplemental
161.0000
161.0000
199.0000
249.0000
407.0000
Total Expenses
55,421.0000
55,421.0000
43,566.0000
50,024.0000
103,433.0000
Net Income from Continuing & Discontinued Operation
-55,361.0000
-55,361.0000
-14,889.0000
-18,053.0000
1,110.0000
Normalized Income
-50,107.5000
-50,107.5000
-13,895.1800
-16,272.5300
-94,438.6613
Interest Expense
2,167.0000
2,167.0000
1,824.0000
943.0000
1,254.0000
Net Interest Income
-2,174.0000
-2,174.0000
-1,826.0000
-718.0000
-901.0000
EBIT
-62,278.0000
-62,278.0000
-10,136.0000
-17,008.0000
-95,482.0000
EBITDA
-60,718.0000
-60,718.0000
-8,158.0000
-15,144.0000
-94,047.0000
Reconciled Cost of Revenue
5,462.0000
5,462.0000
4,116.0000
28,015.0000
30,243.0000
Reconciled Depreciation
1,560.0000
1,560.0000
1,978.0000
1,864.0000
1,435.0000
Net Income from Continuing Operation Net Minority Interest
-55,361.0000
-55,361.0000
-14,889.0000
-18,053.0000
-94,596.0000
Total Unusual Items Excluding Goodwill
-6,650.0000
-6,650.0000
-1,258.0000
-2,439.0000
-160.0000
Total Unusual Items
-6,650.0000
-6,650.0000
-1,258.0000
-2,439.0000
-160.0000
Normalized EBITDA
-54,068.0000
-54,068.0000
-6,900.0000
-12,705.0000
-93,887.0000
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0000
Tax Effect of Unusual Items
-1,396.5000
-1,396.5000
-264.1800
-658.5300
-2.6613
12/31/2020 - 3/13/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PYPD PolyPid Ltd.
4.7525
+4.45%
 
IPHA Innate Pharma S.A.
2.4600
+2.50%
 
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
 
CDT Conduit Pharmaceuticals Inc.
3.1700
+0.32%
 
OBIO Orchestra BioMed Holdings, Inc.
4.3900
-1.13%
 
FBRX Forte Biosciences, Inc.
0.7163
-0.07%
 
XCUR Exicure, Inc.
0.5001
-1.56%
 
CMMB Chemomab Therapeutics Ltd.
0.6399
-2.90%
 
MNPR Monopar Therapeutics Inc.
0.6582
+4.81%
 
SYBX Synlogic, Inc.
1.8700
-1.06%